Incyte's Oral JAK Inhibitor Shows Durable Efficacy, Safety At One Year In Skin Disorder

Incyte Corporation INCY announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).
The study previously met its primary endpoint, demonstrating that at Week 16 – patients receiving povorcitinib once daily (QD) had significantly greater decreases from baseline in Abscess and Inflammatory Nodule (AN) count versus placebo.
Related: Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst.
Results at Week 52, which include the 36-week open-label extension period during which all patients received povorcitinib 75 mg QD, show that average efficacy was sustained for all treatment arms following the switch to povorcitinib 75 mg QD.
Povorcitinib also demonstrated durable efficacy at Week 52 in high-threshold outcomes, as evidenced by 22-29% of patients achieving HS Clinical Response 100 (HiSCR100).
Price Action: INCY shares are down 0.98% at $80.44 on the last check Friday.